1
|
Zhang Y, Lin X, Chen X, Fang W, Yu K, Gu W, Wei Y, Zheng H, Piao J, Li F. Strategies to Regulate the Degradation and Clearance of Mesoporous Silica Nanoparticles: A Review. Int J Nanomedicine 2024; 19:5859-5878. [PMID: 38887691 PMCID: PMC11182361 DOI: 10.2147/ijn.s451919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Accepted: 04/26/2024] [Indexed: 06/20/2024] Open
Abstract
Mesoporous silica nanoparticles (MSNs) have attracted extensive attention as drug delivery systems because of their unique meso-structural features (high specific surface area, large pore volume, and tunable pore structure), easily modified surface, high drug-loading capacity, and sustained-release profiles. However, the enduring and non-specific enrichment of MSNs in healthy tissues may lead to toxicity due to their slow degradability and hinder their clinical application. The emergence of degradable MSNs provided a solution to this problem. The understanding of strategies to regulate degradation and clearance of these MSNs for promoting clinical trials and expanding their biological applications is essential. Here, a diverse variety of degradable MSNs regarding considerations of physiochemical properties and doping strategies of degradation, the biodistribution of MSNs in vivo, internal clearance mechanism, and adjusting physical parameters of clearance are highlighted. Finally, an overview of these degradable and clearable MSNs strategies for biosafety is provided along with an outlook of the encountered challenges.
Collapse
Affiliation(s)
- Yuelin Zhang
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, People’s Republic of China
| | - Xue Lin
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, People’s Republic of China
| | - Xinxin Chen
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, People’s Republic of China
| | - Weixiang Fang
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, People’s Republic of China
| | - Kailing Yu
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, People’s Republic of China
| | - Wenting Gu
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, People’s Republic of China
| | - Yinghui Wei
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, People’s Republic of China
| | - Hangsheng Zheng
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, People’s Republic of China
| | - Jigang Piao
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, People’s Republic of China
| | - Fanzhu Li
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, 310053, People’s Republic of China
| |
Collapse
|
2
|
Chen L, Zhang S, Duan Y, Song X, Chang M, Feng W, Chen Y. Silicon-containing nanomedicine and biomaterials: materials chemistry, multi-dimensional design, and biomedical application. Chem Soc Rev 2024; 53:1167-1315. [PMID: 38168612 DOI: 10.1039/d1cs01022k] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2024]
Abstract
The invention of silica-based bioactive glass in the late 1960s has sparked significant interest in exploring a wide range of silicon-containing biomaterials from the macroscale to the nanoscale. Over the past few decades, these biomaterials have been extensively explored for their potential in diverse biomedical applications, considering their remarkable bioactivity, excellent biocompatibility, facile surface functionalization, controllable synthesis, etc. However, to expedite the clinical translation and the unexpected utilization of silicon-composed nanomedicine and biomaterials, it is highly desirable to achieve a thorough comprehension of their characteristics and biological effects from an overall perspective. In this review, we provide a comprehensive discussion on the state-of-the-art progress of silicon-composed biomaterials, including their classification, characteristics, fabrication methods, and versatile biomedical applications. Additionally, we highlight the multi-dimensional design of both pure and hybrid silicon-composed nanomedicine and biomaterials and their intrinsic biological effects and interactions with biological systems. Their extensive biomedical applications span from drug delivery and bioimaging to therapeutic interventions and regenerative medicine, showcasing the significance of their rational design and fabrication to meet specific requirements and optimize their theranostic performance. Additionally, we offer insights into the future prospects and potential challenges regarding silicon-composed nanomedicine and biomaterials. By shedding light on these exciting research advances, we aspire to foster further progress in the biomedical field and drive the development of innovative silicon-composed nanomedicine and biomaterials with transformative applications in biomedicine.
Collapse
Affiliation(s)
- Liang Chen
- Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, P. R. China.
| | - Shanshan Zhang
- Department of Ultrasound Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P. R. China
| | - Yanqiu Duan
- Laboratory Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, P. R. China.
| | - Xinran Song
- Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, P. R. China.
| | - Meiqi Chang
- Laboratory Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, P. R. China.
| | - Wei Feng
- Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, P. R. China.
| | - Yu Chen
- Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai, 200444, P. R. China.
| |
Collapse
|
3
|
Chen M, Luo J, Jiang W, Chen L, Miao L, Han C. Cordycepin: A review of strategies to improve the bioavailability and efficacy. Phytother Res 2023; 37:3839-3858. [PMID: 37329165 DOI: 10.1002/ptr.7921] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2022] [Revised: 05/24/2023] [Accepted: 05/27/2023] [Indexed: 06/18/2023]
Abstract
Cordycepin is a bioactive compound extracted from Cordyceps militaris. As a natural antibiotic, cordycepin has a wide variety of pharmacological effects. Unfortunately, this highly effective natural antibiotic is proved to undergo rapid deamination by adenosine deaminase (ADA) in vivo and, as a consequence, its half-life is shortened and bioavailability is decreased. Therefore, it is of critical importance to work out ways to slow down the deamination so as to increase its bioavailability and efficacy. This study reviews recent researches on a series of aspects of cordycepin such as the bioactive molecule's pharmacological action, metabolism and transformation as well as the underlying mechanism, pharmacokinetics and, particularly, the methods for reducing the degradation to improve the bioavailability and efficacy. It is drawn that there are three methods that can be applied to improve the bioavailability and efficacy: to co-administrate an ADA inhibitor and cordycepin, to develop more effective derivatives via structural modification, and to apply new drug delivery systems. The new knowledge can help optimize the application of the highly potent natural antibiotic-cordycepin and develop novel therapeutic strategies.
Collapse
Affiliation(s)
- Min Chen
- School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China
- School of Medicine, Linyi University, Linyi, China
| | - Jiahao Luo
- School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China
| | - Wenming Jiang
- School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China
| | - Lijing Chen
- School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China
| | - Longxing Miao
- School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China
| | - Chunchao Han
- School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, China
| |
Collapse
|
4
|
Omar H, Jakimoska S, Guillot J, Alsharaeh E, Charnay C, Cunin F, Bessière A, Durand JO, Raehm L, Lichon L, Onofre M, Gary-Bobo M. Dendritic Mesoporous Organosilica Nanoparticles with Photosensitizers for Cell Imaging, siRNA Delivery and Protein Loading. Molecules 2023; 28:5335. [PMID: 37513209 PMCID: PMC10385246 DOI: 10.3390/molecules28145335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 06/30/2023] [Accepted: 07/04/2023] [Indexed: 07/30/2023] Open
Abstract
Dendritic mesoporous organosilica nanoparticles (DMON) are a new class of biodegradable nanoparticles suitable for biomolecule delivery. We studied the photochemical internalization (PCI) and photodynamic therapy (PDT) of DMON to investigate new ways for DMON to escape from the endosomes-lysosomes and deliver biomolecules into the cytoplasm of cells. We added photosensitizers in the framework of DMON and found that DMON were loaded with siRNA or FVIII factor protein. We made four formulations with four different photosensitizers. The photosensitizers allowed us to perform imaging of DMON in cancer cells, but the presence of the tetrasulfide bond in the framework of DMON quenched the formation of singlet oxygen. Fortunately, one formulation allowed us to efficiently deliver proapoptotic siRNA in MCF-7 cancer cells leading to 31% of cancer cell death, without irradiation. As for FVIII protein, it was loaded in two formulations with drug-loading capacities (DLC) up to 25%. In conclusion, DMON are versatile nanoparticles capable of loading siRNA and delivering it into cancer cells, and also loading FVIII protein with good DLC. Due to the presence of tetrasulfide, it was not possible to perform PDT or PCI.
Collapse
Affiliation(s)
- Haneen Omar
- Chemistry Department, Collage of Science, Alfaisal University, Riyadh 11533, Saudi Arabia
| | - Sara Jakimoska
- IBMM, University Montpellier, CNRS, ENSCM, 34193 Montpellier, France
- ICGM, University Montpellier, CNRS, ENSCM, 34193 Montpellier, France
| | - Julia Guillot
- IBMM, University Montpellier, CNRS, ENSCM, 34193 Montpellier, France
- ICGM, University Montpellier, CNRS, ENSCM, 34193 Montpellier, France
| | - Edreese Alsharaeh
- Chemistry Department, Collage of Science, Alfaisal University, Riyadh 11533, Saudi Arabia
| | - Clarence Charnay
- ICGM, University Montpellier, CNRS, ENSCM, 34193 Montpellier, France
| | - Frédérique Cunin
- ICGM, University Montpellier, CNRS, ENSCM, 34193 Montpellier, France
| | - Aurélie Bessière
- ICGM, University Montpellier, CNRS, ENSCM, 34193 Montpellier, France
| | | | - Laurence Raehm
- ICGM, University Montpellier, CNRS, ENSCM, 34193 Montpellier, France
| | - Laure Lichon
- IBMM, University Montpellier, CNRS, ENSCM, 34193 Montpellier, France
| | - Mélanie Onofre
- IBMM, University Montpellier, CNRS, ENSCM, 34193 Montpellier, France
| | - Magali Gary-Bobo
- IBMM, University Montpellier, CNRS, ENSCM, 34193 Montpellier, France
| |
Collapse
|
5
|
Theivendran S, Lazarev S, Yu C. Mesoporous silica/organosilica nanoparticles for cancer immunotherapy. EXPLORATION (BEIJING, CHINA) 2023; 3:20220086. [PMID: 37933387 PMCID: PMC10624378 DOI: 10.1002/exp.20220086] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Accepted: 02/09/2023] [Indexed: 11/08/2023]
Abstract
Cancer is one of the fatal diseases in the history of humankind. In this regard, cancer immunotherapeutic strategies have revolutionized the traditional mode of cancer treatment. Silica based nano-platforms have been extensively applied in nanomedicine including cancer immunotherapy. Mesoporous silica nanoparticles (MSN) and mesoporous organosilica nanoparticles (MON) are attractive candidates due to the ease in controlling the structural parameters as needed for the targeted immunotherapeutic applications. Especially, the MON provide an additional advantage of controlling the composition and modulating the biological functions to actively synergize with other immunotherapeutic strategies. In this review, the applications of MSN, MON, and metal-doped MSN/MON in the field of cancer immunotherapy and tumor microenvironment regulation are comprehensively summarized by highlighting the structural and compositional attributes of the silica-based nanoplatforms.
Collapse
Affiliation(s)
- Shevanuja Theivendran
- Australian Institute for Bioengineering and NanotechnologyThe University of Queensland, BrisbaneSt LuciaAustralia
| | - Sergei Lazarev
- Australian Institute for Bioengineering and NanotechnologyThe University of Queensland, BrisbaneSt LuciaAustralia
| | - Chengzhong Yu
- Australian Institute for Bioengineering and NanotechnologyThe University of Queensland, BrisbaneSt LuciaAustralia
| |
Collapse
|
6
|
Mezghrani B, Ali LMA, Jakimoska S, Cunin F, Hesemann P, Durand JO, Bettache N. Periodic Mesoporous Ionosilica Nanoparticles for BODIPY Delivery and Photochemical Internalization of siRNA. Chempluschem 2023; 88:e202300021. [PMID: 36779542 DOI: 10.1002/cplu.202300021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 02/10/2023] [Accepted: 02/13/2023] [Indexed: 02/14/2023]
Abstract
Periodic Mesoporous Ionosilica Nanoparticles (PMINPs) made via co-condensation reactions starting from an ionosilica precursor and a porphyrin derivative were used for simultaneous BODIPY/siRNA delivery in cancer cells. We observed high BODIPY loading capacities and efficiencies of the PMINPs that are triggered by anion exchange. siRNA adsorption took place on the surface of the nanoparticles, whereas BODIPY was encapsulated within the core of the nanoparticles. BODIPY release was found to be pH-dependent. Our results indicate 94 % BODIPY release after 16 h at pH 4, whereas only 2 % were released at pH 7.4. Furthermore, complexation with siRNA against luciferase gene was observed at the surface of PMINPs and gene silencing through its delivery via photochemical internalization (PCI) mechanism was efficient in MDA-MB-231 breast cancer cells expressing stable luciferase.
Collapse
Affiliation(s)
- Braham Mezghrani
- IBMM, Univ. Montpellier-CNRS-ENSCM, 1919, route de Mende, 34293, Montpellier Cedex 05, France
- ICGM, Univ. Montpellier-CNRS-ENSCM, 1919, route de Mende, 34293, Montpellier Cedex 05, France
| | - Lamiaa M A Ali
- IBMM, Univ. Montpellier-CNRS-ENSCM, 1919, route de Mende, 34293, Montpellier Cedex 05, France
- Department of Biochemistry Medical Research Institute, Alexandria University, Alexandria, Egypt
| | - Sara Jakimoska
- IBMM, Univ. Montpellier-CNRS-ENSCM, 1919, route de Mende, 34293, Montpellier Cedex 05, France
| | - Frédérique Cunin
- ICGM, Univ. Montpellier-CNRS-ENSCM, 1919, route de Mende, 34293, Montpellier Cedex 05, France
| | - Peter Hesemann
- ICGM, Univ. Montpellier-CNRS-ENSCM, 1919, route de Mende, 34293, Montpellier Cedex 05, France
| | - Jean-Olivier Durand
- ICGM, Univ. Montpellier-CNRS-ENSCM, 1919, route de Mende, 34293, Montpellier Cedex 05, France
| | - Nadir Bettache
- IBMM, Univ. Montpellier-CNRS-ENSCM, 1919, route de Mende, 34293, Montpellier Cedex 05, France
| |
Collapse
|
7
|
Khan MA, Tania M. Cordycepin and kinase inhibition in cancer. Drug Discov Today 2023; 28:103481. [PMID: 36584876 DOI: 10.1016/j.drudis.2022.103481] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 12/09/2022] [Accepted: 12/22/2022] [Indexed: 12/28/2022]
Abstract
Cordycepin, a nucleoside from Cordyceps mushrooms, has many beneficial properties for health, including anticancer activities. In cancer cells, cordycepin targets various signaling molecules. Here, we review the possible anticancer mechanisms of cordycepin involving the targeting of kinases. Abnormal kinase expression is involved in cancer development and progression through different molecular mechanisms, including phosphorylation, amplification, genetic mutations, and epigenetic regulation. Research suggests that kinases, such as the c-Jun N-terminal kinase (JNK), mitogen-activated protein kinase (MAPK), AMP kinase (AMPK), phosphoinositide 3-kinase (PI3K)/Akt, extracellular signal-regulated kinase (ERK), mammalian target of rapamycin (mTOR), glycogen synthase kinase (GSK)-3β, and focal adhesion kinase (FAK) pathways, can be targeted by cordycepin and disrupting their activity. Given that kinase inhibitors can have crucial roles in cancer treatment, targeting kinases might be one of the molecular mechanisms involved in the anticancer potential of cordycepin.
Collapse
Affiliation(s)
- Md Asaduzzaman Khan
- The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan, China; Nature Study Society of Bangladesh, Dhaka, Bangladesh.
| | - Mousumi Tania
- Nature Study Society of Bangladesh, Dhaka, Bangladesh; Division of Molecular Cancer Biology, The Red-Green Research Center, Dhaka, Bangladesh.
| |
Collapse
|
8
|
Le BQG, Doan TLH. Trend in biodegradable porous nanomaterials for anticancer drug delivery. WILEY INTERDISCIPLINARY REVIEWS. NANOMEDICINE AND NANOBIOTECHNOLOGY 2023:e1874. [PMID: 36597015 DOI: 10.1002/wnan.1874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/26/2022] [Revised: 11/21/2022] [Accepted: 11/23/2022] [Indexed: 01/05/2023]
Abstract
In recent years, biodegradable nanomaterials have exhibited remarkable promise for drug administration to tumors due to their high drug-loading capacity, biocompatibility, biodegradability, and clearance. This review will discuss and summarize the trends in utilizing biodegradable nanomaterials for anticancer drug delivery, including biodegradable periodic mesoporous organosilicas (BPMOs) and metal-organic frameworks (MOFs). The distinct structure and features of BPMOs and MOFs will be initially evaluated, as well as their use as delivery vehicles for anticancer drug delivery applications. Then, the themes for the development of each material will be utilized to illustrate their drug delivery performance. Finally, the current obstacles and potential for future development as efficient drug delivery systems will be thoroughly reviewed. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
Collapse
Affiliation(s)
- Bao Quang Gia Le
- Center for Innovative Materials and Architectures, Ho Chi Minh City, Vietnam.,Vietnam National University-Ho Chi Minh City, Ho Chi Minh City, Vietnam.,Department of Chemistry, University of Massachusetts Amherst, Amherst, Massachusetts, USA
| | - Tan Le Hoang Doan
- Center for Innovative Materials and Architectures, Ho Chi Minh City, Vietnam.,Vietnam National University-Ho Chi Minh City, Ho Chi Minh City, Vietnam
| |
Collapse
|
9
|
Mai NXD, Nguyen THT, Nguyen DH, Nguyen LHT, Nguyen HT, Phan TB, Tamanoi F, Vong LB, Doan TLH. Engineering biodegradable periodic mesoporous functionalized-organosilica nanocarriers for efficient paclitaxel delivery. Colloids Surf A Physicochem Eng Asp 2023. [DOI: 10.1016/j.colsurfa.2022.130405] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|